Beroni Group to Build New R&D Center in China

Beroni Group, an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, has signed a contract to build a new Research & Development center in the Zhuhai National High-Tech Industrial Development Zone in China.
 
The new facility will house preclinical research labs, manufacturing process development labs, and a GMP pilot manufacturing plant.
 
The new R&D center — the first R&D site for Beroni — will help the company develop new drugs and medicines to cater for the vast needs of the Chinese market. To start with, the company will occupy about 4,000 square meters (44,000 square feet) of office space for setting up the GMP plant and laboratories. Construction of the new R&D facilities is expected to be completed towards the end of the second quarter, and the entire R&D center is expected to be ready in the second half of this year. Beroni intends to commit $10 million to support the clinical trials in the new R&D facility.
 
A new company, Beroni Pharmaceutical (Guangdong) Co., Ltd, has been established for this new venture with Beroni owning 80% of the entity’s shares and a local investor owning the other 20% shares. The company will bring professional staff, scientists, technicians, and support teams together into a hub for innovation and development of the company’s future products and services.
 
Beroni has a drug development pipeline focusing on oncology and immunotherapy. It is moving ahead with the Phase II clinical trial of the anti-cancer molecular drug, PENAO later this year and is scheduled to commence the clinical trials for a few cellular therapies including gamma delta T cell, DC vaccine, and protein modifier R8. It is also currently studying the use of single-domain antibodies for treatment of coronavirus diseases.
 
“Establishing a new R&D center in Zhuhai will allow us to expand our R&D capabilities and accelerate our innovative pipeline,” said CEO Jacky Zhang. “In the future, we plan to establish additional R&D centers around the world to advance the discovery and development of new innovative product candidates.”